Ambu's Single-Use Products Supplant High-Cost Traditional Technology

Ambu AMBU President and CEO Lars Marcher discusses Ambu's global sales position and growth strategy in an exclusive interview with PropThink.com. According to Marcher, Ambu is adapting traditionally high-cost reusable healthcare technology into significantly cheaper single-use products, which Marcher says is the future of healthcare. A new fiber optic scope, for instance, will cost about $200; the capital requirements and cost-of-ownership for providers are significantly lower than the $60,000 price tag on currently available products from companies like Olympus OCPNY, and 3M MMM in the case of patient-monitoring electrodes.

Marcher discusses revenues for their three product segments - anesthesia, patient monitoring and diagnostics, and emergency training supplies - and explains the company's largest growth segment, as well as impressive regional growth expectations in emerging markets. Marcher also explains why the Danish company is less concerned with European market instability than many competitors and companies based in the EU.

Click here to view our exclusive video interview with Ambu's President & CEO Lars Marcher.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com